This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration. Running time: 20m
Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO FACAAI
Disclosure Information
To download the mp3 file, right click on the player and select Save audio as.
Interested in claiming CME for this episode? Click here!
Additional Episodes in this Miniseries:
Episode 1: Diagnosing HAE Accurately
Episode 3: Long-Term Management and Prophylaxis for HAE
References:
- J. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
- Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
- Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
- Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022
Speaker Disclosures:
All identified relevant financial relationships with ineligible companies have been mitigated.
Kristin C. Sokol, MD, MS, MPH, FACAAI
Advisor: Sanofi, Genentech, SELF/Conde Nast
Jonathan A. Bernstein, MD, FACAAI
Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech , GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva
Timothy J. Craig, DO FACAAI
Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda
Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda
Independent Contractor: Kalvista, Phavaris
Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda
Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
This podcast miniseries is supported by a grant from Takeda.